Even with interest broadly running hot in 2024, don’t expect Barnes & Thornburg to announce a merger anytime soon. The leader of the Am Law 100 firm said in an interview this month that its growth mantra is mostly “philosophically” at odds with combinations, and the Indianapolis-founded firm would only consider it “if a…

Lawyers See New Barriers to IVF, Despite Well-Meaning Legislation | Connecticut Law Tribune Page Printed From: https://www.law.com/ctlawtribune/2024/03/20/lawyers-see-new-barriers-to-ivf-despite-well-meaning-legislation/ Credit: Bigstock ANALYSIS “There’s been a rush based on this Alabama Supreme Court decision without thinking through the, hopefully, unintended consequences, which are common patient rights and preventing people’s access to justice,” attorney…

McMillan has grabbed a five-lawyer banking and financial services team from Dentons Canada to boost its presence in western Canada. Partners Gary Rose, Glen Peterson, Ben Nuttall and David Fendley will be based in the firm’s growing Calgary office, and associate Adam Palmer will work out of Vancouver. Rose said…

House Republicans are seeking to reform the U.S. Securities and Exchange Commission with the introduction of 13 bills and claims that the agency is exceeding its current statutory authority with its hasty and aggressive rulemaking agenda. The bills would, among other procedural disclosures, require the SEC to provide an assessment…

The fact that a single drug’s development is at the center of multiple lawsuits against Gilead Sciences subsidiary Immunomedics Inc. doesn’t mean a D&O insurance provider can’t provide coverage in each case, Superior Court Judge Paul R. Wallace decided on Monday. Wallace granted the California-based biotech company’s motion for partial summary judgment and denied…

At least three Big Law firms are steering AstraZeneca’s proposed acquisition of Amolyt Pharma, a French clinical-stage biotechnology company, in a deal valued at up to $1.05 billion. Freshfields Bruckhaus Deringer said it was counseling U.K.-based AstraZeneca, while Jones Day and Cooley said they were advising Amolyt Pharma, which is…